GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP's Role in Tirzepatide

Tirzepatide's superior efficacy compared to semaglutide in the SURPASS-2 trial raised fundamental questions about GIP's contribution. Several hypotheses explain how GIP agonism enhances GLP-1 agonist effects: (1) GIP may reduce GLP-1-mediated nausea by modulating central emetic circuits, enabling better tolerability and adherence at effective doses; (2) GIP receptor activation in adipose tissue may improve lipid buffering capacity, reducing ectopic fat deposition; (3) high-dose GIP agonism may cause GIPR internalization and functional antagonism ("agonist-induced desensitization"), achieving effects similar to GIPR blockade; (4) GIP may enhance GLP-1's central anorexigenic effects through complementary hypothalamic pathways.

GIP in the Incretin Effect

GIP was the first incretin identified, preceding the discovery of GLP-1. In healthy individuals, GIP is responsible for the majority of the incretin effect. K-cells in the proximal small intestine secrete GIP rapidly in response to glucose, fat, and protein ingestion, with peak levels achieved within 15-30 minutes. The incretin effect of GIP is mediated through glucose-dependent insulin secretion enhancement, identical in principle to GLP-1 but acting through distinct receptor signaling cascades. Baggio LL & Drucker DJ (2007) — Gastroenterology 132, 2131-2157.

Ongoing & Future Research

Active areas of GIP research include:

• GIP Agonism vs. Antagonism Resolution: Clinical trials with GIPR antagonist antibodies (e.g., AMG 133 by Amgen, a bispecific GLP-1 agonist/GIPR antagonist, NCT05669599) will help resolve whether agonism or antagonism is superior in combination with GLP-1R agonism for obesity treatment.

• GIP and Bone Health: Long-term studies are investigating whether GIP receptor agonism in tirzepatide and retatrutide provides bone-protective effects, given GIP's known anabolic effects on osteoblasts. This could be a differentiating advantage over GLP-1-only agents in older patients at risk for osteoporosis.

• Central GIP Signaling: Research into GIPR expression and function in the brain is ongoing, with efforts to understand how GIP contributes to appetite regulation, nausea modulation, and potentially neuroprotection. The hypothalamic expression of GIPR suggests roles beyond metabolic regulation.

• GIP Resistance Mechanisms: Understanding why the beta cell response to GIP is impaired in type 2 diabetes (but apparently overcome by supraphysiological agonism in tirzepatide) remains a fundamental research question with implications for drug design.

• Next-Generation Multi-Agonists: GIP receptor agonism is being incorporated into novel multi-agonist peptides targeting various combinations of metabolic receptors (GIPR, GLP-1R, GcgR, FGFR, amylin receptors) for optimized metabolic outcomes.

The GIP Agonism vs. Antagonism Debate

A paradox has emerged in GIP biology: both GIP receptor agonism (as in tirzepatide) and GIP receptor antagonism (as in experimental anti-obesity antibodies) can produce weight loss in preclinical and clinical studies. GIPR agonism in tirzepatide is associated with improved GI tolerability and enhanced weight loss compared to GLP-1 alone, possibly through central appetite suppression, improved lipid handling, or receptor desensitization at high agonist concentrations. Conversely, GIPR antagonism may reduce lipid storage in adipose tissue and shift metabolism toward fat oxidation. This controversy suggests that the relationship between GIP signaling and energy balance is complex and context-dependent. Killion EA et al. (2018) — Sci. Transl. Med. 10, eaat3392.

Clinical Research Protocols

As an endogenous hormone, GIP itself is not administered as a therapeutic agent due to its ~5-7 minute half-life. Clinical research involving GIP typically uses controlled infusion protocols:

GIP Infusion Studies: Continuous IV infusion at 1-4 pmol/kg/min to achieve supraphysiological plasma GIP levels. Used in acute metabolic studies to characterize insulin secretion, glucagon response, and lipid metabolism effects. Studies comparing GIP response in healthy controls versus type 2 diabetes patients have been instrumental in characterizing "GIP resistance."

Incretin Clamp Studies: Hyperglycemic clamp combined with GIP and/or GLP-1 infusion to quantify the insulinotropic potency of each incretin independently and in combination. These studies demonstrate the additive effects of dual incretin stimulation. Nauck MA et al. (1993) — PMID: 8423228

Meal Tolerance Tests with GIP Measurement: Standard mixed-meal tolerance tests with serial blood sampling for total and intact GIP at 0, 15, 30, 60, 90, and 120 minutes post-meal. Intact GIP measurement requires DPP-4 inhibitor-treated sample tubes to prevent ex vivo degradation.

GIP Resistance in Type 2 Diabetes

A critical difference between GIP and GLP-1 in the context of type 2 diabetes is that the insulinotropic response to GIP is severely impaired in type 2 diabetes (termed "GIP resistance"), while the response to GLP-1 is largely preserved. This observation initially led researchers to focus therapeutic development on GLP-1 rather than GIP. The mechanism of GIP resistance is not fully understood but may involve downregulation of GIPR expression on beta cells, impaired post-receptor signaling, or chronic hyperglycemia-induced desensitization. Importantly, the success of tirzepatide suggests that supraphysiological GIP receptor agonism can overcome this resistance or that GIP's therapeutic benefits in the context of dual agonism extend beyond direct beta cell effects. Nauck MA et al. (1993) — J. Clin. Invest. 91, 301-307.

Comparison to Related Compounds

GIP vs. GLP-1: Despite both being incretins, GIP and GLP-1 have important differences: (1) GIP is the quantitatively dominant incretin in health but loses effectiveness in type 2 diabetes; (2) GLP-1 strongly suppresses glucagon while GIP has bidirectional effects; (3) GLP-1 powerfully slows gastric emptying while GIP has minimal effect; (4) GLP-1 has potent central anorexigenic effects while GIP's appetite role is debated; (5) GIP has prominent effects on adipose tissue and bone that GLP-1 lacks. Nauck MA & Meier JJ (2018) — PMID: 30132036

GIP in Tirzepatide: Tirzepatide's GIP agonist component is thought to contribute to its superior efficacy over semaglutide through enhanced gastrointestinal tolerability, improved adipose tissue lipid handling, and complementary central appetite effects. The exact mechanism remains an active research question.